All In Biotech

Drug Trial Radar · NCT07387549

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

Apr 30, 2031

Study completion May 31, 2031

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Feb 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC). PSC is a rare disease that causes inflammation and scarring of the bile ducts in the liver. Over time, this can lead to liver damage and serious health problems, including the need for a liver transplant and death. In this study, about 350 participants with large duct PSC will take part. Participants will be randomized to receive either elafibranor 120 mg once daily or a placebo (a tablet with no active medicine). The study includes a screening period, an treatment period, and a post-treatment safety follow-up. During the study, participants will undergo routine clinical assessments, laboratory testing, imaging evaluations, and complete patient-reassessments to evaluate liver disease progression, symptoms, quality of life and safety. Following the end of treatment, participants will complete a safety follow-up period at approximately four weeks. Participants may withdraw from the study at any time. Each participant may be in the study for several years, as the treatment period will continue until the study reaches enough health events among participants, which is expected to take about 5 years.

Conditions

  • Primary Sclerosing Cholangitis

Interventions

  • ElafibranorDrug

    Round and orange film coated tablet of 120 mg

  • PlaceboOther

    Round and orange film coated tablet of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free SurvivalTime frame: From baseline until the end of treatment (estimated up to 5 years)

Locations

231 sites in 25 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Chandler, Arizona · Recruiting

  • Mayo Clinic in Arizona

    Phoenix, Arizona · Not yet recruiting

  • Southern California Research Center

    Coronado, California · Recruiting

  • University of California San Diego

    La Jolla, California · Not yet recruiting

  • Keck Medicine of USC - USC Healthcare Center 1

    Los Angeles, California · Not yet recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Not yet recruiting

  • California Liver Research Institute

    Pasadena, California · Recruiting

  • Stanford University

    Redwood City, California · Not yet recruiting

  • University of California Davis Medical Center

    Sacramento, California · Not yet recruiting

  • Sutter Health Van Ness Campus Medical Office Building

    San Francisco, California · Not yet recruiting

  • University of California, San Francisco Medical Center

    San Francisco, California · Recruiting

  • University of Colorado Hospital Anschutz Outpatient Pavilion

    Aurora, Colorado · Not yet recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • South Denver Gastroenterology,P.C.

    Englewood, Colorado · Recruiting

  • Rocky Mountain Gastroenterology (RMG)

    Littleton, Colorado · Recruiting

  • Yale Medical Group - Yale Digestive Diseases -Temple Medical Center Location

    New Haven, Connecticut · Not yet recruiting

  • MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)

    Washington D.C., District of Columbia · Not yet recruiting

  • University of Miami - Schiff Center for Liver Diseases

    Miami, Florida · Recruiting

  • Piedmont Hospital - Piedmont Transplant Institute

    Atlanta, Georgia · Not yet recruiting

  • Northwestern Medicine

    Chicago, Illinois · Not yet recruiting

  • Rush University Medical Center

    Chicago, Illinois · Not yet recruiting

  • The University of Chicago Medicine

    Chicago, Illinois · Not yet recruiting

  • Indiana University School of Medicine

    Indianapolis, Indiana · Recruiting

  • Gastroenterology Health Partners, PLLC (Southern Indiana Location)

    New Albany, Indiana · Not yet recruiting

  • Deaconess GI Specialty Center

    Newburgh, Indiana · Not yet recruiting

  • The University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Recruiting

  • University Of Louisville School Of Medicine

    Louisville, Kentucky · Not yet recruiting

  • Mercy Medical Center, Inc

    Baltimore, Maryland · Recruiting

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Not yet recruiting

  • University of Michigan

    Ann Arbor, Michigan · Not yet recruiting

  • Henry Ford Health System

    Detroit, Michigan · Not yet recruiting

  • Mayo Clinic Cancer Center (MCCC) - Rochester

    Rochester, Minnesota · Not yet recruiting

  • Saint Louis University

    St Louis, Missouri · Not yet recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Not yet recruiting

  • NYU Langone Gastroenterology and Hepatology Associates

    New York, New York · Not yet recruiting

  • Weill Medical College Of Cornell University

    New York, New York · Not yet recruiting

  • Mount Sinai Medical Center

    New York, New York · Not yet recruiting

  • University of Rochester Medical Center

    Rochester, New York · Not yet recruiting

Showing 40 of 231 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.